Keyphrases
AAV Gene Therapy
100%
Mucopolysaccharidosis IVA
100%
Skeletal Alterations
100%
Adeno-associated Viral Vector
33%
Serotype 9
33%
GALNS
33%
Keratan Sulfate
33%
Gene Therapy
16%
Lysosomal Storage Disease
16%
Body Size
16%
Rat Model
16%
Size Reduction
16%
Cartilage
16%
Peripheral Tissues
16%
Whole-body
16%
Life-threatening
16%
Bone Tissue
16%
Trachea
16%
Clinical Translation
16%
Enzyme Replacement Therapy
16%
Bone Cartilage
16%
CRISPR-Cas9 Technology
16%
Cartilage Tissue
16%
Skeletal Dysplasia
16%
Skeletal Abnormalities
16%
N-acetylgalactosamine-6-sulfate Sulfatase
16%
Morquio A Disease
16%
Chondroitin-6-sulfate
16%
Sulfate Accumulation
16%
Medicine and Dentistry
Gene Therapy
100%
Adeno-Associated Virus
100%
Mucopolysaccharidosis
100%
Adeno Associated Virus Vector
33%
Serotype
33%
Keratan Sulfate
33%
Diseases
16%
Deterioration
16%
Enzyme Replacement Therapy
16%
Trachea
16%
Clustered Regularly Interspaced Short Palindromic Repeat
16%
Cas9
16%
Lysosomal Storage Disease
16%
Storage Disease
16%
Bone Dysplasia
16%
Sulfatase
16%
Skeleton Malformation
16%
Sulfate
16%
Chondroitin 6 Sulfate
16%
N Acetylgalactosamine
16%
Pharmacology, Toxicology and Pharmaceutical Science
Mucopolysaccharidosis
100%
Adeno Associated Virus Vector
33%
Keratan Sulfate
33%
Rat Model
16%
Replacement Therapy
16%
Disease
16%
Lysosome Storage Disease
16%
Storage Disease
16%
Deterioration
16%
Sulfatase
16%
Skeleton Malformation
16%
Bone Dysplasia
16%
N Acetylgalactosamine
16%
Chondroitin 6 Sulfate
16%
Sulfate
16%